Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

Akston Biosciences Corp

CIK 1776612Updated Oct 6, 2026

No exchange listing on record for this SEC filer. Coverage is drawn from its filings.

Filing activity

SEC EDGAR
Latest filing

FWP · May 4, 2026

8 filings on record · FWP, S-1/A.

About the company

We are a pet biotechnology company focused on the development and commercialization of innovative biopharmaceutical products for cats, dogs, and other companion animals. We believe the pet health market is experiencing rapid growth, with increasing demand for innovative treatments that enhance pet longevity and quality of life. According to the American Pet Products Association, U.S. consumers spent an estimated $152 billion on their pets in 2024. Within this total, the veterinary care and pharmaceutical sales segment accounted for $39.8 billion. A key driver of this growth has been the companion animal therapeutics segment, which has expanded from $12.5 billion in 2015 to a projected $23.7 billion in 2025, representing a compound annual growth rate of 6.6%. Our current product portfolio includes multiple product candidates consisting of large molecule biologics that are designed to target significant opportunities in serious medical conditions in pets such as urothelial carcinoma (bladder cancer) in dogs, atopic dermatitis in dogs, chronic pain associated with arthritis in dogs, and obesity and metabolic disease in cats.

S-1/A · 2026-05-04 · 0001104659-26-054475

Company description from the cited filing.

Offerings

Registration 333-290778

S-1/A · 2026-05-04 · 0001104659-26-054475

Terms from the governing filing for this registration; not a claim that the offering is open today.

Underwriters: ThinkEquity LLC

Filing attachments

tm2516611d17_ex4-1.htm · S-1/A · 2026-01-15

Exhibit 4.1 ★ D EL AWA R E ★ SEAL AKSTON BIOSCIENCES CORPORAT OI N CORPORATE DECEMBER 28, 2011 FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.000001 PAR VALUE PER SHARE, OF Akston Biosciences Corporation transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certificate properly endorsed. This Certificate is not valid until countersigned by the Transfer Agent and registered by the Registrar. WITNESS the facsi…

S-1/A · 2026-01-15 · 0001104659-26-004158

Read attachment ↗
tm2516611d17_ex4-2.htm · S-1/A · 2026-01-15

Exhibit 4.2 Form of Representative’s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER THAN (I) THINKEQUITY LLC, OR …

S-1/A · 2026-01-15 · 0001104659-26-004158

Read attachment ↗
tm2516611d17_ex4-3.htm · S-1/A · 2026-01-15

Exhibit 4.3 AKSTON BIOSCIENCES CORPORATION REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 21, 2025, is entered into by and among Akston Biosciences Corporation, a Delaware corporation (the “Company”), and the investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors The Company and the Investors may be referred to herein each as a “Party” and collectively…

S-1/A · 2026-01-15 · 0001104659-26-004158

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.